All News

The approval was based on a confirmatory trial that found the therapy slowed disease progression compared with placebo.

Researchers concluded that older patients with stable MS can stop taking disease-modifying therapy because risk of relapse is so small.

The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.

What's on the agenda for FTP in the upcoming month?

Odevixibat can now be used to treat cholestatic pruritus in young patients with Alagille syndrome (ALGS).

A study presented at Digestive Disease Week 2023 compared the effectiveness of different approaches to prevent complications in individuals with the common disease.

Delayed prophylaxis start and intermediate dose intensity of factor VIII prevents bleeds, but at a cost of more joint damage and possibly a lower QOL.

Your weekly roundup of the latest news from Drug Topics®.

What stood out on Sunday and Monday at the 2023 ASHP Summer Meetings in Baltimore?

Your weekly roundup of the latest news from Drug Topics®.

Advisers with the FDA endorse a monoclonal antibody treatment for RSV in children, AstraZeneca and Quell sign a $2 billion agreement, and HSS hopes to strengthen the pediatric workforce.

The newly approved at-home test was effective in trials, correctly identifying 98.7% of negative and 92.9% of positive samples for individuals with symptoms of upper respiratory infection.

A survey shows cancer centers are struggling, Google expands its generative AI into health care, and the WHO announces enhanced collaboration with the Global Fund.

The median annual cost for new oncology medicines launched in 2022 was $260,000, up from $63,534 10 years ago, an IQVIA report finds.

Cue Health gets FDA’s first de novo approval for at-home COVID-19 test, Novavax says its new vaccine will fight new variants and HHS creates new cert standards for peer support workers.

Existing evidence-evaluation frameworks are not sufficiently targeted toward the specific factors relevant to digital health products, they argue.

Merck sues the federal government, the FDA will allow cancer drug imports from China, and a drug from GSK shows promise for endometrial cancer treatment.

The combination of Lynparza and abiraterone reduced the risk of disease progression or death by 76% vs. abiraterone alone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Patients were more likely to require ICU admission.

Mandy Cohen is set to become the next CDC director, Medicare will cover a new class of Alzheimer’s drugs, and the WHO announces a landmark digital health initiative.

Your weekly roundup of the latest news from Drug Topics®.

More than 11.6 million treatment courses of the medication have been prescribed in the U.S. to date.

Individuals with type 1 diabetes (T1D) had brain atrophy patterns equivalent to a brain age about 6 years older than their actual age.

The frequency of drug manufacturer coupon utilization is associated with more market competition—but not patients’ out-of-pocket costs.

Quality of life (QOL) for people living with autoimmune diseases benefits from an integrated approach that considers individual immune system sensitivities and patients’ life circumstances, a new study shows.

Part of the risk of developing kidney involvement begins when type 1 diabetes mellitus (T1DM) sets in and establishes itself in the patient, with up to 65% of children experiencing acute kidney injury during T1DM onset, which can further predispose to the development of future chronic kidney disease.